Five former LifeMD workers told the health-news outlet STAT that clinicians at the telehealth company were pushed to clear GLP-1 weight-loss cases at a pace of roughly two minutes each. LifeMD strenuously denies it. Nothing has been proven, no regulator has acted, and — the part readers keep asking about — there is no patient class action and nothing to claim.
Status: Allegations reported | No class action over prescribing | No claim form, no deadline
What Was Reported
On July 20, 2026, STAT published an investigation into LifeMD, Inc., one of the larger direct-to-consumer telehealth companies writing prescriptions for GLP-1 weight-loss drugs such as Wegovy. The reporting drew on interviews with five former employees and on two lawsuits brought by former senior leaders of the company.
The through-line of the accounts is pace. Former staff described being pressed to move faster than they thought was clinically defensible, working from electronic intake forms that patients had filled in themselves. Two of them put a number on it: clinicians were at times expected to review the cases of 25 people an hour. That is about two minutes a file, and the queue they described mixed brand-new patients in with refill requests that stepped a patient up to a higher dose.
Three further complaints came with it. Providers said they were discouraged from asking questions they considered medically relevant — questions about medical history, other conditions, and screening for disordered eating — on the reasoning that extra questions slow care down. Patient messages, they said, were routed through medical assistants rather than straight to a clinician, which could leave a reported side effect sitting in a queue for days. And refills, they said, were approved in batches.
LifeMD’s chief executive, Justin Schreiber, rejected the premise outright, telling STAT the company’s objective “has not been to run a pill mill” and that it has “actually taken the opposite position.” Our sister site covers the reporting and the company’s response in full in Did LifeMD Rush GLP-1 Prescriptions? What Ex-Workers Say.
There Is No Patient Class Action Here
This matters enough to say without hedging. As of this writing, no consumer class action over LifeMD’s GLP-1 prescribing has been identified. No class has been certified. No regulator has announced an enforcement action against the company over these allegations. There is no settlement, no claim form, and no deadline to miss.
What exists is journalism plus two employment disputes. The two suits are between LifeMD and former executives; their allegations are sworn, but untested. The other accounts are interviews given to a news organisation. A former employee’s description of an internal productivity target is not a finding that the target existed, that anyone was punished for missing it, or that a single patient was hurt by it.
Where Two Minutes Stops Being Enough
Obesity medicine is not a baroque specialty, but it does contain a handful of steps that take longer than two minutes and do not tolerate being skipped. The reason the reported figure landed the way it did is that the accounts line up against those steps almost item for item.
Confirming who the patient physically is
A GLP-1 prescription is supposed to rest on a documented weight and body mass index. On an asynchronous platform, those arrive as digits a patient typed into a web form. A two-minute file review does not verify them against anything. Someone who is not clinically overweight and wants the drug does not need a convincing story — only a number.
Baseline bloodwork
A metabolic panel, thyroid function and HbA1c exist to catch the conditions that make these drugs risky for a particular person. Former staff said prescriptions were sometimes issued before results came back, or before anyone read them. A lab order nobody waits for is paperwork, not a gate.
The dose-escalation pause
These medications start low and step up slowly on purpose, because the step-ups are where serious gastrointestinal, pancreatic and renal problems tend to appear. The protection is not the schedule — it is the pause inside it, when somebody checks how the patient handled the last dose. Batch-approving a refill queue deletes the pause and leaves a calendar behind.
What happens when a patient says something is wrong
Severe vomiting, dehydration, or abdominal pain that might be pancreatitis are time-sensitive. If those messages sit with non-clinical staff first, the delay is itself the harm, no matter how good the eventual reply is.
Why Speed Has a Price Tag
LifeMD runs a vertically integrated stack: an intake portal that collects the questionnaire and the payment details, an affiliated medical group licensed across all 50 states that reviews those intakes and writes the prescriptions, an in-house pharmacy operation, and an administrative layer that handles prior authorisations and shipping. Very little of the chain is bought in, which is how the company reached a gross margin near 89% in the second quarter of 2026, up roughly 280 basis points year over year.
The revenue is not transactional. About 84% of it is recurring subscription income, and the company reported roughly 356,000 active subscribers at the end of that quarter, up 20% year over year, with about 108,000 of them in the weight-management programme.
Put those two facts together and the structural point makes itself. In a subscription business, the initial clinical review is the turnstile into a recurring monthly relationship. An intake that clears becomes a subscriber; an intake that stalls does not. When the clinical decision sits directly on the conversion funnel, the incentive gradient runs toward yes and toward fast. Noting that is not proof anybody acted on it — but it is why a figure like 25 files an hour drew the attention it did.
If Anything Comes of This, It Probably Will Not Be a Class Action
The likelier route runs through professional licensing law, and it turns on two doctrines most readers have never had reason to learn.
The clinician–patient relationship standard. Nearly every state requires a valid clinician–patient relationship before a prescription drug can be written: an adequate history, informed consent, and a documented judgement that this drug suits this person. States loosened much of this during the COVID-19 emergency to make remote care workable, and a good deal of the rulemaking since has been tightening it again, with more weight on documented history-taking and an articulable diagnostic basis. Counselling duties live here too — patients are meant to be told about risks including gastroparesis, acute kidney injury and the thyroid C-cell tumour warning these drugs carry. Whether that fits inside two minutes is precisely the question a state medical board would ask, and boards regulate the individual clinician’s licence rather than the platform’s marketing.
Corporate practice of medicine. The second doctrine is the sharper one. Many states bar non-physician corporations from practising medicine or from directing the clinical judgement of licensed professionals — which is exactly why telehealth companies operate through a nominally independent affiliated medical group. A corporate cases-per-hour quota sits close to the centre of what that rule was written to prevent. If a company sets a throughput target and attaches consequences to missing it, a regulator could characterise that as the corporation steering clinical judgement, whatever the org chart says. That is what makes the specific allegation unusual: the claim is not that a doctor made a bad call, it is that a corporation set the clock. No state board has announced an inquiry into LifeMD, and the company’s account — independent clinicians who keep full discretion to order labs, require a video visit, or decline — is the standard answer to that theory.
What Enforcement Against Telehealth Has Actually Looked Like
LifeMD has not been sued or sanctioned over any of this. Two recent federal actions against other GLP-1 telehealth companies are worth knowing anyway, because they show where the agencies have been aiming — and it is not clinical adequacy.
In July 2025 the FTC sued NextMed over its GLP-1 weight-loss programmes, alleging misleading pricing, unsubstantiated weight-loss claims, fake testimonials, distorted reviews, and a failure to obtain informed consent before recurring charges. Monthly fees of roughly $138 to $188, the Commission said, did not actually cover the drugs, the required labs, or the provider consultations. A final order approved in December 2025 required a $150,000 payment expected to fund consumer refunds, plus substantiation obligations going forward.
Then on July 29, 2026 — nine days after the LifeMD reporting — the FTC, joined by the State of Utah and Los Angeles County, sued Hims & Hers Health in the Northern District of California, alleging the company shared sensitive health information with advertising platforms including Meta and Snap while marketing itself as private, charged customers before provider consultations, and made subscriptions hard to cancel. The claims run under Section 5 of the FTC Act and the Restore Online Shoppers’ Confidence Act. Hims & Hers denies wrongdoing and the case is unresolved. We covered an earlier consumer case against the same company in claims that Hims & Hers enrolled users in a subscription without clear notice.
Neither action involves LifeMD, and neither alleges prescribing-pace conduct. What they establish is the division of labour: the FTC reaches billing, cancellation, advertising claims and data handling. Clinical adequacy is left largely to state medical boards.
Why Novo Nordisk Keeps Appearing in Coverage
Novo Nordisk is not accused of the prescribing conduct. It turns up because of a commercial relationship that gives the story reach beyond one company.
Since 2025 LifeMD’s work with Novo Nordisk has grown from an integration with the drugmaker’s NovoCare Pharmacy into a broader arrangement covering injectable and oral Wegovy and Ozempic, and LifeMD is listed as a telehealth provider on both the NovoCare and Wegovy sites. On March 31, 2026 LifeMD announced it was offering Novo Nordisk’s multi-month Wegovy subscription programme, alongside other telehealth partners, at fixed monthly pricing for eligible self-pay patients. The arrangement is not exclusive: in March 2025 LifeMD integrated with Gifthealth, the pharmacy behind Eli Lilly’s LillyDirect self-pay channel, to ship single-dose Zepbound vials.
The published cash-pay prices show what these channels are for. Wegovy starter doses have been offered at $199 a month for a new patient’s first fills; Ozempic through NovoCare Pharmacy has run roughly $199 to $499 a month depending on dose and patient status; the oral Wegovy pill launched at an introductory $149 a month after FDA approval in late 2025, with increases announced for higher maintenance doses from April 15, 2026. Cash-pay GLP-1 pricing has moved repeatedly — check current figures with the platform before relying on any of these.
Facing formulary exclusions and coverage fights with pharmacy benefit managers, the manufacturers have been building direct cash-pay channels that route patients through named telehealth partners. Naming a partner is a form of vouching for it, and reputational exposure travels both directions along that channel. That is why a story about one company’s internal workflow was read as a story about the sector.
The Federal Squeeze on GLP-1 Telehealth
These allegations landed in the middle of an escalating federal push against how GLP-1 drugs are marketed online. That push targets a different problem — compounded copies of semaglutide and tirzepatide and the claims made for them — but it is the backdrop the prescribing allegations are being read against.
- September 2025 — the FDA sends warning letters to more than 50 compounders and manufacturers over misleading claims about compounded GLP-1 products.
- March 3, 2026 — warning letters go to 30 telehealth companies over false or misleading claims about compounded semaglutide and tirzepatide, including representations that compounded versions are the same as the approved drugs.
- June 16, 2026 — a further 25 letters on the same theme.
- 2026 — the FDA moves to remove semaglutide, tirzepatide and liraglutide from the list of drugs outsourcing facilities may compound, which would close the large-scale compounding pipeline.
No FDA warning letter to LifeMD has been identified in that wave, and the letters concern marketing claims rather than prescribing pace. Separately, LifeMD told investors on August 5, 2026 that roughly 95% of its new weight-management patients now start on branded GLP-1 therapies, and that its transition away from compounded versions is effectively complete.
The Other LifeMD Matters, and Why They Are Not This One
A search for “LifeMD investigation” returns several things at once. They are frequently blurred together, and they are not the same.
A securities class action. Johnston v. LifeMD, Inc. was filed August 27, 2025 in the Eastern District of New York. Investors allege the company made materially false or misleading statements about its 2025 outlook, in particular by raising full-year guidance in May 2025 without properly accounting for rising customer-acquisition costs in its RexMD segment. LifeMD cut that guidance on August 5, 2025 and the stock fell roughly 45% the next day. Those are allegations; there has been no finding of liability. The case concerns disclosures to shareholders, not the care any patient received.
A privacy settlement that is finished. In W.M.F. & Matthew Marden v. LifeMD, Inc., in Clark County, Nevada, users alleged that tracking technologies on LifeMD’s websites, including RexMD, disclosed identifiable health information to third parties such as Meta, Google and TikTok. The parties settled with no admission of wrongdoing — $10 in cash or a $25 voucher per class member — final approval came on September 30, 2025, and distributions began January 21, 2026. The claim window is shut. We set out the timeline and payment status in our report on the LifeMD and RexMD privacy settlement.
A California privacy investigation that is open. This one is live and it is not the Nevada case. Attorneys are examining whether the intake questionnaires on LifeMD and its Rex MD and ShapiroMD brands passed a visitor’s answers to third-party advertising networks before that visitor accepted the terms or created an account — which would reach prospective patients rather than the members and purchasers the Nevada class covered. It is limited to California residents who started a questionnaire on or before June 14, 2026. Nothing has been filed and nothing has been proven; the LifeMD data privacy investigation page sets out who may qualify. Details are in the panel at the end of this article.
Two older items that circulate without their endings. In April 2021 a securities class action, Owens v. LifeMD, Inc., was filed in the Southern District of New York; it was voluntarily dismissed on May 18, 2021, about a month later, and its allegations were never tested. And in November 2025 LifeMD postponed a third-quarter earnings release after identifying corrections to how it had recognised revenue across 2023, 2024 and the first half of 2025 — a cumulative effect of roughly $4.6 million, or about 1.4% of the revenue reported over those periods. The company called it a revision rather than a restatement. It is a governance data point, not a patient-safety one.
What to Do If You Get GLP-1 Drugs Online
There is no case against LifeMD for patients to join. What the reporting offers is a set of questions worth putting to any telehealth platform prescribing these drugs:
- Did a licensed clinician actually review your history, or did an intake form alone produce the prescription?
- Were you screened for other conditions, for interacting medications, and for a history of disordered eating?
- When you report a side effect, does it reach a clinician — and how fast?
- Are dose escalations reviewed one at a time, or applied on a schedule?
- Are you receiving the FDA-approved branded drug or a compounded version, and do you know which?
Do not stop a prescribed medication because of a news story. Raise concerns with a licensed clinician. If you have a severe or persistent reaction, seek care and consider reporting it to the FDA’s MedWatch programme, which is how adverse events enter the federal safety data. Keep your prescription records, visit notes and platform messages.
Patients who say a GLP-1 drug physically injured them are in an entirely different posture, and their claims run against the manufacturers rather than a telehealth prescriber. Those are consolidated in federal multidistrict litigation — we track the gastrointestinal-injury side in our coverage of the Ozempic gastroparesis mass tort. Neither that litigation nor this reporting has a settlement or a claim form.
What Would Change the Picture
Three things, none of which has happened. A state medical board or a federal agency could open something public. The two employment suits could reach discovery, at which point internal targets and communications become testable rather than described secondhand. Or plaintiffs’ firms could file, typically framed as a claim that patients paid for a level of medical care they did not receive.
Frequently Asked Questions
Is there a class action against LifeMD over GLP-1 prescribing?
No. No consumer class action over LifeMD’s GLP-1 prescribing has been identified, no class has been certified, and there is no settlement or claim form. The allegations reported in July 2026 come from former employees interviewed by STAT and from two lawsuits filed by former senior leaders, which are employment disputes rather than patient cases. LifeMD denies the allegations and no court has found it liable.
What exactly did the former employees say?
Five former employees told STAT that clinicians were pushed to work faster than was clinically responsible. Two said providers were at times expected to review 25 patient cases an hour — roughly two minutes each — working only from self-completed intake forms. They also said providers were discouraged from asking questions they considered medically relevant, and that routing patient messages through medical assistants delayed responses to reported side effects. These are unproven allegations.
Has any regulator acted against LifeMD?
Not on these allegations. No state medical board inquiry has been announced and no FDA warning letter to LifeMD has been identified. The FDA has been active against the wider sector — 30 telehealth companies received warning letters on March 3, 2026 and another 25 in June 2026 — but those concerned marketing claims about compounded semaglutide and tirzepatide, not prescribing pace.
Is Novo Nordisk accused of anything here?
No. Novo Nordisk appears in the story because of a commercial relationship: LifeMD is listed as a telehealth provider on the NovoCare and Wegovy websites, and in March 2026 it was one of several telehealth companies offering Novo Nordisk’s multi-month Wegovy subscription programme. That relationship is why the allegations drew industry-wide attention.
Is there any open LifeMD matter I could actually be part of?
One, and it is about privacy rather than prescribing. Attorneys are investigating whether LifeMD, Rex MD and ShapiroMD intake questionnaires passed visitors’ answers to third-party advertising networks before those visitors accepted the terms or created an account. It is limited to California residents who started a questionnaire on or before June 14, 2026 and who never accepted the terms, created an account or made a purchase. No complaint has been filed and no class has been certified.
What should I do if I take a GLP-1 drug from a telehealth service?
Keep taking a prescribed medication only under a clinician’s direction, and raise concerns with a licensed medical professional rather than stopping on your own. If you have severe or persistent side effects, seek care and report the event to the FDA’s MedWatch programme. Save your prescription records, visit notes and messages with the platform. This article is informational and is not medical or legal advice.
Sources
- STAT, “LifeMD, a popular telehealth firm, put profits over patient safety, ex-workers say,” July 20, 2026 — the originating investigation, including the former employees’ accounts and the company’s denial.
- U.S. Food & Drug Administration — warning letters to 30 telehealth companies, March 3, 2026, and a further 25 in June 2026; guidance for telehealth companies promoting compounded drugs; semaglutide safety information.
- Federal Trade Commission — action against NextMed over GLP-1 weight-loss programme marketing, July 2025, and final order, December 2025.
- Federal Trade Commission, State of Utah and Los Angeles County v. Hims & Hers Health, N.D. Cal., filed July 29, 2026.
- LifeMD press releases — Novo Nordisk Wegovy telehealth subscription programme, March 31, 2026; LillyDirect pharmacy integration for Zepbound, March 6, 2025; Second Quarter 2026 Results, August 5, 2026.
- SEC EDGAR — LifeMD, Inc. periodic filings, including the company’s legal-proceedings disclosures.
- OpenClassActions.com, Did LifeMD Rush GLP-1 Prescriptions? What Ex-Workers Say and LifeMD & RexMD Privacy Settlement Closed: Payment Status.
By Felix Levine | Published: September 10, 2026
Legal Disclaimer
This article is for informational purposes only and is not legal or medical advice. OpenClassActions.org is a consumer news site, not a law firm, and is not affiliated with LifeMD, Inc., Rex MD, ShapiroMD, Novo Nordisk, Eli Lilly, Hims & Hers Health or any party described above. The allegations reported here are unproven and LifeMD denies them; no court or regulator has made any finding against the company on them. Consult a licensed attorney about your own situation, and a licensed clinician about your own care.